Clinical Trials


Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

This study has been completed
Pacgen Biopharmaceuticals Corporation

Quintiles, Inc.

Information provided by (Responsible Party)
Pacgen Biopharmaceuticals Corporation Identifier

First received: March 18, 2008
Last updated: June 25, 2008
Last Verified: June 2008
History of Changes


The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.

Condition Intervention Phase
Oral Candidiasis

Drug : PAC113
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113

Further study details as provided by Pacgen Biopharmaceuticals Corporation:

Primary Outcome Measures

  • Eliminating or reducing clinical signs and symptoms of oral Candida infections. [ Time Frame: Day 19 ]
Secondary Outcome Measures:
  • To evaluate the microbiological response of Candida to different concentrations of PAC-113. [ Time Frame: Day 19 ]

Enrollment: 223
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: 1
PAC113 0,15% mouthrinse
Drug: PAC113

PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Experimental: 2
PAC113 0,075% mouthrinse
Drug: PAC113

PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Experimental: 3
PAC113 0,0375% mouthrinse
Drug: PAC113

PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Active Comparator: 4
Nystatin suspension
Drug: PAC113

PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Detailed Description:

This is a randomized, examiner-blinded, positive-controlled, parallel design clinical trial, which features 4 treatment arms. Forty-five (45)* HIV positive subjects per treatment arm will be recruited for 180 subjects total. The study includes 5 visits: a screening visit, a 14-day treatment phase with a baseline visit on Day 1, a Day 7 visit, a post-treatment visit 5 days after the last dose, and follow-up visit. During the screening visit subjects will be assessed for study eligibility. Eligible subjects will be randomized to 1 of the following treatment arms:
A. 0.15% PAC-113 mouthrinse (5 mL 4 times daily [q.i.d.]); B. 0.075% PAC-113 mouthrinse (5 mL q.i.d.); C. 0.0375% PAC-113 mouthrinse (5 mL q.i.d.); D. Nystatin oral suspension (100,000 units/mL; 5 mL q.i.d.) Subjects will be evaluated clinically for safety and severity of clinical signs and symptoms of oral candidiasis at baseline (Day 1), Day 7, Day 19 (5 days post-treatment) and Day 28 (follow-up visit). Subjects will also have a microbiological analysis performed at screening, and at Days 7, 19 and 28.



Ages Eligible for Study: 18 Years to 65 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Are male or female 18 to 65 years of age, inclusive
  • Are able and willing to follow study procedures and instructions
  • Are able to read, understand and sign an informed consent form
  • Are documented as HIV positive
  • Have pseudomembranous and/or erythematous oral candidiasis as confirmed by potassium hydroxide preparation of mucosal scraping
  • Have a CD4 cell count performed prior to randomization or within 6 weeks prior to the screening visit
  • Have a viral load performed prior to randomization or within 6 weeks prior to the screening visit.
  • Both men and women who are active heterosexually must be willing to practice a medically accepted method of birth control.

Exclusion Criteria:
  • Have received systemic antifungal therapy within 14 days of starting study
  • Have received prior topical therapy for oral candidiasis within 7 days of starting study
  • Have a concomitant fungal infection requiring systemic therapy
  • Are currently receiving immunosuppressive therapy (e.g. corticosteroids), or cancer chemotherapy
  • Female subjects who are pregnant (as determined by a positive serum or urine pregnancy test) or lactating, or female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control (e.g., oral or parenteral contraceptives, diaphragm plus spermicide, condoms) or who have not characterized themselves as abstinent. Subjects who use hormonal contraceptives must have started the method at least 30 days prior to the screening examination
  • Active substance abuse
  • Have esophageal symptoms (dysphagia or odynophagia) unless esophageal candidiasis has been ruled out by endoscopy
  • Have a life expectancy < 4 weeks
  • Are currently receiving or have received an investigational agent in the last 30 days
  • Have had a change in antiretroviral therapy within 14 days prior to study entry (this does not apply to dose adjustment of the same therapy)
  • Have any of the following laboratory abnormalities:
    • White blood cell (WBC) count <1,500 cells/mm3
    • Neutrophil granulocyte count <1,000 cells/mm3
    • Hemoglobin <9.0/dL
    • Transaminases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) or bilirubin >3 times the upper limit of normal (ULN)
    • Serum creatinine >2 times ULN
  • Have peri-oral lesion (perleche) only
  • Have oral manifestations of herpes simplex (active disease only), hairy leukoplakia
and/or aphthous ulcers

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00659971


United States, North Carolina
Rosedale Infectious Disease
Huntersville, North Carolina, United States, 28078

Sponsors and Collaborators

Pacgen Biopharmaceuticals Corporation
Quintiles, Inc.
More Information

More Information

Responsible Party: Pacgen Biopharmaceuticals Corp., Director, Drug Development Identifier: NCT00659971   History of Changes  
Other Study ID Numbers: PBC002-01  
Study First Received: March 18, 2008  
Last Updated: June 25, 2008  

Keywords provided by Pacgen Biopharmaceuticals Corporation:

oral candidiasis

Additional relevant MeSH terms:
HIV Seropositivity
Candidiasis, Oral processed this data on September 21, 2018
This information is provided by